Erin Trish and Dana Goldman argue eliminating drug rebates will increase the cost of Medicare Part D premiums, but most seniors will be not feel the effects. They say seniors should ignore pharmacy benefit managers' alarm raised by the proposal.
Pharmaceutical Pricing and Medical Innovation
Other featured articles
The U.S. should assess the economic value of drugs rather than leave it up to other countries
Why are prescription drugs are often priced lower overseas? Many countries perform detailed assessments of the economic value of drugs and their benefits, and this could work in the U.S., says William Padula
The Bigger Message Behind Amgen’s Decision to Slash Cost of its Repatha Cholesterol Drug
Drug companies look to haggle less and sell more, and that could cost Express Scripts, CVS Health and UnitedHealth writes Goldman in MarketWatch.
White House Signs Bills Banning Gag Clauses, Schaeffer Center Research Pivotal in Discussion
Schaeffer Center report found 23 percent of private claims analyzed involved a copayment that exceeded the insurer’s cost of the drug.
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.